EVH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evolent Health Inc (EVH) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock is experiencing significant downward pressure, with declining revenue, high leverage, and limited visibility into EBITDA recovery. Additionally, there are no strong positive catalysts or proprietary trading signals to support a buy decision.
The MACD histogram is positive at 0.122, indicating slight bullish momentum, but it is contracting. RSI is neutral at 60.706, and moving averages are converging, showing no clear trend. Support and resistance levels suggest limited upside potential in the short term, with key resistance at 3.584 and support at 2.671.
The company's new CFO, Mario Ramos, is implementing transparency and conservatism in guidance. Gross margin has improved YoY, and analysts maintain Buy ratings despite lowering price targets.
The company has high leverage (7x) and limited visibility into EBITDA recovery. Analysts have drastically reduced price targets, and the stock is under pressure due to medical cost concerns and ACA exchange membership impact. No recent news or congress trading data to act as a positive catalyst.
In Q4 2025, revenue dropped by -27.50% YoY to $468.7M. Net income improved to -$429.1M, up 1301.70% YoY, but remains negative. EPS increased to -3.85, up 1325.93% YoY. Gross margin improved to 11.14%, up 55.15% YoY. However, the overall financial performance remains weak.
Analysts maintain Buy ratings but have significantly lowered price targets. UBS reduced the target to $5, Citi to $4, and Canaccord to $4. KeyBanc downgraded the stock to Sector Weight due to high leverage and lack of EBITDA recovery visibility.
